Physician
Anvar Medical Group
Anvar Medical Group was paid $792K by Medicaid between Jan 2018 and Dec 2024, across 32 billing codes. Its largest line is 99204, doctor's office visit, new patient (more involved) — 31% of everything it billed.
33Billing provider infoANVAR MEDICAL GROUP
NORTHRIDGE, CA 91324
NORTHRIDGE, CA 91324
33aNPI1831539485assigned 06/27/2013
33bProvider typeSurgery Physician
28Total paid$792K
24GClaims39,870
24DCodes billed32
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Surgery Physician providers in California
Rank by total paid#33 of 437
Median peer was paid$23K
This provider vs. median35×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,245 | $32K | |
| 2019 | 4,060 | $83K | |
| 2020 | 4,318 | $88K | |
| 2021 | 8,347 | $133K | |
| 2022 | 9,622 | $133K | |
| 2023 | 6,486 | $190K | |
| 2024incomplete | 4,792 | $133K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 31% | 4,902 | 4,849 | $246K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 30% | 5,256 | 4,479 | $235K |
| 99205 | Prolong outpt/office vis | 13% | 6,799 | 5,856 | $105K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 9.4% | 2,825 | 2,484 | $74K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 6.9% | 4,864 | 3,954 | $55K |
| S9083 | Global fee urgent care centers | 2.1% | 516 | 501 | $17K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.6% | 2,743 | 1,815 | $13K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.4% | 1,754 | 1,234 | $11K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.2% | 881 | 856 | $10K |
| 99000 | <1% | 3,314 | 2,449 | $6K | |
| 11043 | <1% | 224 | 94 | $5K | |
| 99051 | <1% | 2,203 | 2,149 | $3K |
20 more codes
| A6250 | Skin sealants, protectants, moisturizers, ointments, any type, any size | <1% | 899 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 68 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 667 | $1K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 132 | $1K |
| 99326 | <1% | 54 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 19 | $900.00 |
| 99334 | <1% | 126 | $886.50 | |
| 99335 | <1% | 84 | $833.03 | |
| 81003 | <1% | 675 | $790.02 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 533 | $563.75 |
| 86328 | <1% | 43 | $461.38 | |
| 81025 | <1% | 30 | $287.77 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 29 | $286.00 |
| A9150 | Non-prescription drugs | <1% | 98 | $107.00 |
| 81000 | <1% | 53 | $100.10 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 19 | $100.00 |
| 36415 | Collection of venous blood by venipuncture | <1% | 16 | $98.00 |
| 81002 | <1% | 13 | $4.26 | |
| 99070 | 0% | 15 | $0.00 | |
| 36416 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANVAR, BARDIA (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Skilled Facility Health Care Solutions INC | Los Angeles, CA | $17.81M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.